Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice

Journal of Immunotherapy

Volumn 34, Issue 1, 2011, Pages 76-84

  Johnson, Erik E ^a   Buhtoiarov, Ilia N ^a   Baldeshwiler, Mark J ^a   Felder, Mildred A R ^b   Van Rooijen, Nico ^b   Sondel, Paul M ^a,c   Rakhmilevich, Alexander L ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

anti CD40 mAb; CpG; cyclophosphamide; immunotherapy; macrophages

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD40; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; MACROPHAGE ACTIVATION; MELANOMA B16; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FLOW CYTOMETRY; IMMUNOCOMPETENCE; KILLER CELLS, NATURAL; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, SCID; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES;

EID: 78650652525     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318200b28a     Document Type: Article

References (48)

1. Assouline S, Sylvestre MP, Carriere P, et al. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients. Transfusion. 2006;2:174-179.
2. Dang CT. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions. Expert Rev Anticancer Ther. 2006;3:427-436. Review.
3. Rosti G, Carminati O, Monti M, et al. Chemotherapy advances in small cell lung cancer. Ann Oncol. 2006;17(suppl 5):v99-v102. Review.
4. Borovansky J. Experimental chemotherapy of murine melanomas: is there a discrepancy compared to clinical experience? Neoplasma. 1997;44:277-281.
5. Goldfarb RH, Ohashi M, Brunson KW, et al. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide. Anticancer Res. 1998;18:1441-1446.
6. Holden SA, Lan Y, Pardo AM, et al. Augmentation of antitumor activity of an antibody-interleukin 2 immunocyto-kine with chemotherapeutic agents. Clin Cancer Res. 2001;7: 2862-2869.
7. North RJ. Cyclophosphamide-facilitated adoptive immu-notherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155: 1063-1074.
8. Lutsiak ME, Semnani RT, De PR, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862-2868.
9. Yu B, Kusmartsev S, Cheng FD, et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res. 2003;9:285-294.
10. Sredni B, Weil M, Khomenok G, et al. Ammonium trichloro (dioxoethylene-o,o) tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 2004;64:1843-1852.
11. Eralp Y, Wang XY, Wang JP, et al. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004;6:R275-R283.
12. Mitchell MS. Combinations of anticancer drugs and immu-notherapy. Cancer Immunol Immunother. 2003;52:686-692.
13. Solomayer EF, Feuerer M, Bai L, et al. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res. 2003;9:174-180.
14. Dye ES, North RJ. Macrophage accumulation in murine ascites tumors. 1. Cytoxan-induced dominance of macrophages over tumor-cells and the antitumor effect of endotoxin. J Immunol. 1980;125:1650-1657.
15. Tsung K, Dolan JP, Tsung YL, et al. Macrophages as effector cells in interleukin 12-induced T-cell-dependent tumor rejection. Cancer Res. 2002;62:5069-5075.
16. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113:1387-1395.
17. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol. 2000;68:455-463.
18. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005;105:489-495.
19. Law CL, Gordon KA, Collier J, et al. Preclinical antilym-phoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;18:8331-8338.
20. Leonard JP, Link BK, Emmanouilides C, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007;13: 6168-6174.
21. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-883.
22. Murad YM, Clay TM, Lyerly HK, et al. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther. 2007;7:1257-1266. Review.
23. + T-cell reactivity in melanoma patients. Clin Cancer Res. 2008;14:4532-4542.
24. Buhtoiarov IN, Lum HD, Berke G, et al. Synergistic activation of macrophages via CD40 and TLR9 results in T-cell independent antitumor effects. J Immunol. 2006;176:309-318.
25. Imboden M, Murphy KR, Rakhmilevich AL, et al. The level of MHC class I expression on murine adenocarcinoma can change the anti-tumor effector mechanism of immunocytokine therapy. Cancer Res. 2001;61:1500-1507.
26. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83-93.
27. Fink K, Ng C, Nkenfou C, et al. Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur J Immunol. 2009;39: 2809-2821.
28. Gordon S, Lawson L, Rabinowitz S, et al. Antigen markers of macrophage differentiation in murine tissues. Curr Top Microbiol Immunol. 1992;181:1-37.
29. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004;200:771-782.
30. Awwad M, North RJ. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. 1988;65:87-92.
31. Liu JY, Wu Y, Zhang XS, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother. 2007;56: 1597-1604.
32. Turner JG, Rakhmilevich AL, Burdelya L, et al. Anti-CD40 antibody induces antitumor and anti-metastatic effects: role of natural killer cells. J Immunol. 2001;166:89-94.
33. Buhtoiarov IN, Lum H, Berke G, et al. CD40 ligation induces antitumor reactivity of murine macrophages via an IFN gamma-dependent mechanism. J Immunol. 2005;174:6013-6022.
34. Buhtoiarov IN, Sondel PM, Eickhoff JC, et al. Macrophages are essential for antitumor effects against weakly immunogenic murine tumors induced by class B CpG-ODN. Immunology. 2007;120:412-423.
35. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:4249-4258.
36. Nardin A, Lefebvre ML, Labroquere K, et al. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosar-coma. Curr Cancer Drug Targets. 2006;6:123-133. Review.
37. Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res. 1995;1:1595-1601.
38. Klimp AH, De Vries EG, Scherphof GL, et al. Chemo-immunotherapy of ovarian cancer in a murine tumour model. Anticancer Res. 2000;20:2585-2592.
39. Meyers PA, Schwartz CL, Krailo MD, et al; Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-638.
40. Angulo I, de las Heras FG, Garcia-Bustos JF, et al. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood. 2000;95:212-220.
41. Pelaez B, Campillo JA, Lopez-Asenjo JA, et al. Cyclophos-phamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol. 2001;166:6608-6615.
42. Honeychurch J, Glennie MJ, Illidge TM. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B-cell lymphoma is dependent on CD11b+ cells. Cancer Res. 2005;65:7493-7501.
43. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubi-cin-cyclophosphamide chemotherapy. Cancer Immunol Immuno-ther. 2009;58:49-59.
44. Lum HD, Buhtoiarov IN, Berke G, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol. 2006;79: 1181-1192.
45. Ribechini E, Leenen PJ, Lutz MB. Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol. 2009;39:3538-3551.
46. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315-322. Review.
47. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituxi-mab and cyclophosphamide-doxorubicin- vincristine-predni-sone. Clin Cancer Res. 2007;13:5784-5789.
48. Guiducci C, Vicari AP, Sangaletti S, et al. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65:3437-3446.